Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innovent Biologics ( (HK:1801) ) has issued an announcement.
Innovent Biologics has entered a new strategic collaboration with Eli Lilly and Company to co-develop novel oncology and immunology medicines, marking the seventh partnership between the two firms and underscoring a deepening, long-term alliance. Under the deal, Innovent will lead discovery and development through Phase 2 proof-of-concept in China, after which Lilly will hold exclusive rights to develop and commercialize the resulting products outside Greater China, while Innovent maintains rights within Greater China; in return, Innovent will receive a US$350 million upfront payment, up to approximately US$8.5 billion in potential milestones, and tiered royalties on ex-Greater China sales. The partnership is positioned by Innovent as a new end-to-end innovation model that combines its agile R&D engine with Lilly’s global scale, potentially accelerating the global rollout of its pipeline and reinforcing Innovent’s standing as a Chinese biotech capable of generating assets with worldwide commercial prospects.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$83.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative biologic drugs, with particular emphasis on oncology and immunology. Leveraging robust antibody technology platforms and clinical development capabilities in China, the company targets both the domestic Chinese market—where it retains commercial rights to its pipeline—and global markets through strategic partnerships with multinational pharma groups.
YTD Price Performance: 4.26%
Average Trading Volume: 11,778,926
Technical Sentiment Signal: Buy
Current Market Cap: HK$137.9B
See more insights into 1801 stock on TipRanks’ Stock Analysis page.